Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives $24.00 Consensus Target Price from Brokerages

by · The Cerbat Gem

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) have been assigned a consensus recommendation of “Hold” from the eighteen brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eleven have given a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $24.00.

TNDM has been the topic of several research reports. Barclays upped their price objective on Tandem Diabetes Care from $51.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, November 10th. Sanford C. Bernstein reissued a “market perform” rating and set a $25.00 price target (up from $18.00) on shares of Tandem Diabetes Care in a research report on Friday, January 9th. Mizuho lifted their price objective on shares of Tandem Diabetes Care from $18.00 to $21.00 and gave the stock a “neutral” rating in a report on Wednesday, December 17th. Stifel Nicolaus initiated coverage on shares of Tandem Diabetes Care in a report on Tuesday, October 21st. They set a “hold” rating and a $15.00 target price on the stock. Finally, Citigroup lifted their price target on shares of Tandem Diabetes Care from $16.00 to $22.00 and gave the company a “neutral” rating in a report on Thursday, December 11th.

View Our Latest Report on Tandem Diabetes Care

Tandem Diabetes Care Stock Down 4.3%

TNDM traded down $0.91 during trading on Friday, hitting $20.16. The company had a trading volume of 1,377,238 shares, compared to its average volume of 1,087,133. Tandem Diabetes Care has a 1-year low of $9.98 and a 1-year high of $37.93. The company has a debt-to-equity ratio of 2.33, a current ratio of 2.44 and a quick ratio of 1.90. The company has a market cap of $1.37 billion, a PE ratio of -6.61 and a beta of 1.68. The business has a 50-day moving average of $20.99 and a 200-day moving average of $16.35.

Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last released its earnings results on Thursday, November 6th. The medical device company reported ($0.31) earnings per share for the quarter, hitting the consensus estimate of ($0.31). Tandem Diabetes Care had a negative net margin of 20.19% and a negative return on equity of 73.97%. The company had revenue of $249.25 million during the quarter, compared to the consensus estimate of $235.80 million. During the same quarter in the previous year, the firm earned ($0.35) EPS. The company’s revenue was up 2.2% on a year-over-year basis. As a group, analysts forecast that Tandem Diabetes Care will post -1.68 earnings per share for the current year.

Institutional Trading of Tandem Diabetes Care

A number of large investors have recently modified their holdings of TNDM. Banque Pictet & Cie SA increased its stake in shares of Tandem Diabetes Care by 29.6% in the fourth quarter. Banque Pictet & Cie SA now owns 97,187 shares of the medical device company’s stock valued at $2,136,000 after purchasing an additional 22,205 shares during the period. CoreCap Advisors LLC increased its position in Tandem Diabetes Care by 24.4% in the 4th quarter. CoreCap Advisors LLC now owns 5,909 shares of the medical device company’s stock valued at $130,000 after acquiring an additional 1,158 shares during the period. Assenagon Asset Management S.A. bought a new stake in Tandem Diabetes Care during the 4th quarter valued at $26,988,000. Diversified Trust Co. boosted its position in Tandem Diabetes Care by 6.6% during the 4th quarter. Diversified Trust Co. now owns 19,558 shares of the medical device company’s stock worth $430,000 after acquiring an additional 1,219 shares during the period. Finally, 180 Wealth Advisors LLC grew its stake in shares of Tandem Diabetes Care by 29.3% in the fourth quarter. 180 Wealth Advisors LLC now owns 13,443 shares of the medical device company’s stock worth $295,000 after purchasing an additional 3,047 shares in the last quarter.

About Tandem Diabetes Care

(Get Free Report)

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.

Read More